Bristol-Myers Squibb Company Ce
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $253.5M
- Price
- $0.1035
- Volume
- 2.2M
About
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
Quick stats
Shares outstanding2.0B
Computed float2.0B
Float / shares99.9%
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000014272
Websitehttp://www.bms.com
AI Summary
AI-generated1/50
standardbullishclinical trial
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
SystImmune and Bristol Myers Squibb reported positive Phase 3 PANKU-Lung01 interim results for iza-bren in previously-treated EGFR-mutated NSCLC, with median PFS of 11.1 months versus 5.7 months for platinum-based chemotherapy (HR 0.40, p<0.0001).
Response rates also favored iza-bren (60.2% vs 34.5% cORR) with a manageable safety profile, and the data were presented at ESMO 2026 and published in The Lancet.
Outside China, iza-bren is jointly developed by SystImmune and BMY under a collaboration and exclusive license agreement; the asset has FDA Breakthrough Therapy Designation and clinical benefit across five tumor types.
Red flags
- OS data immature - favorable trend only, not yet significant
- Grade >=3 TRAEs predominantly hematologic; China-sponsored trial, regulatory filings outside China not yet approved